ARTV
Artiva BiotherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case assumes positive late-stage signals, a favorable labeling pathway or buyout interest leading to a significant re-rate; limited near-term dilution and execution on partnerships support valuation expansion.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -17.7.
What can break
Bear case assumes trial setbacks or need for heavy dilution to fund programs, compressing per-share value; small float and low liquidity can exacerbate selling pressure.
Momentum
74
Value
42
Sentiment
18
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.76 · Bull $7.62 · Bear $2.54
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-21 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum74 · Δ7d -17.7
Value42 · Δ7d +0.1
Sentiment18 · Δ7d +5.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
74
34% active weight
Current posture
7d trendSoftening
Δ7d
-17.7
Δ21d
-24.5
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
18
33% active weight
Current posture
7d trendImproving
Δ7d
+5.7
Δ21d
+12.4
Why this grade
Composite grade D. Momentum 74.4 / Value 41.9 / Sentiment 17.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$169.8M
Beta
-
Shares Out
24.54M
P/E (TTM) · Derived
-2.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.14
Rev YoY
-100.0%
EPS YoY
+4.9%
Gross Margin
-
Op Margin
-26806.4%
Net Debt
-$185.26M
Current Ratio
11.65
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology